Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

25C-NBOMe

From PsychonautWiki Archive
Revision as of 22:25, 3 January 2019 by >Dextromethorphan (added od section)
Jump to navigation Jump to search

25C-NBOMe can be fatal at heavy doses (as low as 4mg).[1]

It is strongly discouraged to take large amounts of this substance or to insufflate (snort) it. Please see this section for more details.

Summary sheet: 25C-NBOMe
25C-NBOMe
Chemical Nomenclature
Common names 25C-NBOMe, Cimbi-82, NBOMe-2C-C, 2C-C-NBOMe
Substitutive name 2C-C-NBOMe
Systematic name [[systematic name::2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine]]
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.





Sublingual
Dosage
Threshold 50 µg
Light 100 - 300 µg
Common 300 - 700 µg
Strong 700 - 1000 µg
Heavy 25C-NBOMe can be fatal at heavy doses.[1]
Duration
Total 8 - 10 hours
Onset 0 - 15 minutes
Come up 30 - 90 minutes
Peak 4 - 6 hours
Offset 1 - 4 hours







DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
2C-T-X
5-MeO-xxt
Caffeine
Cannabis
DOx
MAOIs
MDMA
MXE
Amphetamines
aMT
Cocaine
DXM
Tramadol
Lithium


25C-NBOMe (also known as Cimbi-36, 2C-C-NBOMe, and "N-Bomb", although this term is used broadly to refer to the entire 25x-NBOMe family) is a novel psychedelic substance of the phenethylamine class. It produces an array of visually-dominant and stimulating psychedelic effects when administered.

The name 25C-NBOMe, which is short-hand for 2C-C-NBOMe, is a derivative of the phenethylamine psychedelic 2C-C. It was discovered in 2003 by Ralf Heim at the Free University of Berlin,[2] and subsequently investigated by a team at Purdue University led by David Nichols.[3] It has been studied in its radiolabelled form as a potential ligand for mapping the distribution of serotonin-2A receptors in the brain, using positron emission tomography (PET).[4][5]

Users note that compounds of the NBOMe family are not orally active and should be administered sublingually by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes. 25C-NBOMe can also be vaporized and inhaled for more rapid and powerful effects and a shorter duration. However, this route of administration is highly advised against due to the difficulties of measuring and handling substances that are both active in the microgram range which highly elevates the risk of overdose.

25C-NBOMe had no history of human use before being sold online as a designer drug in 2010.[citation needed] Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25C-NBOMe in humans, and it has been associated with many deaths and hospitalizations. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to approach this poorly understood psychedelic substance with the proper amount of precaution and harm reduction practices if choosing to use it.

Blotter paper containing 25C-NBOMe

Chemistry

25C-NBOMe or 2C-C-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as 2C-C. 25C-NBOMe is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as a chlorine atom attached to carbon R4. It differs from 2C-C structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group as shown in the image to the right. 25C-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH3O- bound to a benzene ring at R2.

Pharmacology

Further information: Serotonergic psychedelic

25C-NBOMe has efficacy at the 5-HT2A receptor where it acts as a potent partial agonist.[6] However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

In comparison to 2C-C, the addition of an NBOMe group to the structure results in a sixteen fold increase in potency, allowing even the most extreme of dosages to fit in liquid form onto tabs and blotter paper, which people often mistake for LSD.[7] In comparison to LSD however it is only a third of the potency.[8]

Subjective effects

The cognitive effects of 25C-NBOMe are commonly described as being notably light and underwhelming in comparison to more traditional psychedelics. It is not uncommon for user to report feeling that their thought stream has maintained a normality in style throughout low to moderate dosages. At high dosages, however, mild to overwhelming cognitive alterations become present; this dosage seems to be lower in proportion to physical effects when compared to 25I-NBOMe.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Transpersonal effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

25C-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The LD50 has not yet been determined although it can be fatal at heavy dosages.[9] 25C-NBOMe overdoses have also been linked to multi-organ failure.[10][11]

It is advised that due to 25C-NBOMe's extreme potency it should not be insufflated (snorted) as this method of administration has been attributed to several fatal overdoses due to improper dosing.[12][9]

It is strongly recommended that one use harm reduction practices when using this substances.

Tolerance and addiction potential

25C-NBOMe is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 25C-NBOMe are built almost immediately after ingestion. After that, it takes about 7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). 25C-NBOMe presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 25C-NBOMe all psychedelics will have a reduced effect.

Overdose

Due to the very high potency and seemingly unpredictable effects the margin between a normal and an overdose of NBOMe compounds is extremely small when compared to many other substances. The exact toxic dose is unclear since it seems to depend a lot on personal physiology, rather than predominantly dose. However, various anecdotal reports suggest that dangerous side effects begin to appear when exceeding 1000 μg and it possibly becoming lethal for the more sensitive people at roughly 2000 μg. Reports of other people surviving much higher doses, sometimes even without any major side effects have been documented as well.

There is also the uncertainty of dosage on blotter paper since it is rather difficult to lay such an exact dosage. Insufflating, vaporizing or drinking tinctures of this substance is highly discouraged because of this and has been tied to many documented deaths[13][1][14]. One study found that 25I‐NBOMe and 25C‐NBOMe blotter papers contained 'hotspots' with higher quantities of the drug, implying an inherent risk of overdosing.[15]

The overdose effects of NBOMes are typically a dangerously high heart rate, blood pressure, hyperthermia and significant vasoconstriction[16][17] also accompanied by confusion, delusions, panic attacks, aggressive behavior, numbness or pain, amnesia and often seizures. The risks in an overdose include anything from organ failure to cardiac arrest and death[citation needed]. There are also multiple reports of people lethally injuring themselves or falling to death[18][19]. Benzodiazepines or antipsychotics can help with the psychological effects during an overdose although medical attention should always be called in even a possible overdose of 25I-NBOMe.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • [[Wikipedia:Lithium_(medication)|DangerousInteraction::Lithium]] - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
  • "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of 25C-NBOMe. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
  • "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.[citation needed]
  • "[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Tramadol is well-documented to lower the seizure threshold[20] and psychedelics may act to trigger seizures in susceptible individuals.[citation needed]
  • Austria: 25C-NBOMe is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[21]
  • Canada: 25C-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[22]
  • China: As of October 2015 25C-NBOMe is a controlled substance in China.[23]
  • Germany: Possession, production and sale is illegal.[24]
  • Israel: The NBOMe series of psychoactives became controlled in Israel in May, 2013.[25]
  • Italy: In Italy 25C-NBOMe is a Schedule 1 controlled substance, meaning it's illegal in this state.[26]
  • Latvia: 25C-NBOMe is a Schedule I controlled substance.[27]
  • New Zealand 25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.[28]
  • Russia: Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.[29][30]
  • Sweden: 25C-NBOMe is classed as Schedule I.[31]
  • United Kingdom: 25C-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.[32]
  • United States: Several NBOMe series compounds will be temporarily scheduled in the United States for 2 years with the possibility of an additional year. The temporary scheduling applies to 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe.[33]

See also

Discussion

References

  1. 1.0 1.1 1.2 Erowid 2C-C-NBOMe (25C-NBOMe) Vault : Fatalities / Deaths 
  2. Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.
  3. Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.
  4. https://www.ncbi.nlm.nih.gov/pubmed/21174090
  5. http://bitnest.ca/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V
  6. Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24397362
  7. 25C-NBOMe--new potent hallucinogenic substance identified on the drug market (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/22989597
  8. http://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_dose.shtml
  9. 9.0 9.1 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid - https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
  10. Fatal intoxication with the new designer drug 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/26324189
  11. Near fatal intoxication with the novel psychoactive substance 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24770890
  12. Near fatal intoxication with the novel psychoactive substance 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24770890
  13. Erowid 25I-NBOMe (2C-I-NBOMe) Vault : Fatalities / Deaths 
  14. Erowid NBOMe (Other or Unknown NBOMe-Compound) Vault : Fatalities / Deaths 
  15. Lützen, E., Holtkamp, M., Stamme, I., Schmid, R., Sperling, M., Pütz, M., Karst, U. (April 2020). "Multimodal imaging of hallucinogens 25C‐ and 25I‐NBOMe on blotter papers". Drug Testing and Analysis. 12 (4): 465–471. doi:10.1002/dta.2751. ISSN 1942-7603. 
  16. Marchi, N. C., Scherer, J. N., Fara, L. S., Remy, L., Ornel, R., Reis, M., Zamboni, A., Paim, M., Fiorentin, T. R., Wayhs, C. A. Y., Von Diemen, L., Pechansky, F., Kessler, F. H. P., Limberger, R. P. (1 March 2019). "Clinical and Toxicological Profile of NBOMes: A Systematic Review". Psychosomatics. 60 (2): 129–138. doi:10.1016/j.psym.2018.11.002. ISSN 0033-3182. 
  17. Yoon, K. S., Yun, J., Kim, Y.-H., Shin, J., Kim, S. J., Seo, J.-W., Hyun, S.-A., Suh, S. K., Cha, H. J. (1 April 2019). "2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo". Toxicology Letters. 304: 50–57. doi:10.1016/j.toxlet.2019.01.004. ISSN 0378-4274. 
  18. https://psychonautwiki.org/wiki/File:Nbome_death_news_i2013e0190_disp.jpg
  19. https://psychonautwiki.org/wiki/File:Nbome_death_news_i2013e0191_disp.jpg
  20. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  21. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  22. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
  23. 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html
  24. BtMG Anlage I | https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html
  25. https://www.erowid.org/chemicals/nbome/nbome_law.shtml
  26. Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf
  27. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  28. ‘Legal high’ DIME not so legal | http://www.sciencemediacentre.co.nz/2012/03/13/legal-high-dime-not-so-legal/
  29. https://www.erowid.org/chemicals/nbome/nbome_law.shtml
  30. Постановление Правительства Российской Федерации от 6 октября 2011 г. N 822 г. Москва | http://www.rg.ru/2011/10/19/narko-dok.html
  31. Läkemedelsverkets författningssamling - http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf
  32. United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made
  33. DEA proposed rules | http://www.gpo.gov/fdsys/pkg/FR-2013-10-10/pdf/2013-24432.pdf